206 related articles for article (PubMed ID: 24126361)
81. In vitro antiviral activity of arbidol against Chikungunya virus and characteristics of a selected resistant mutant.
Delogu I; Pastorino B; Baronti C; Nougairède A; Bonnet E; de Lamballerie X
Antiviral Res; 2011 Jun; 90(3):99-107. PubMed ID: 21440006
[TBL] [Abstract][Full Text] [Related]
82. Association of toll-like receptor polymorphisms with susceptibility to chikungunya virus infection.
Dutta SK; Tripathi A
Virology; 2017 Nov; 511():207-213. PubMed ID: 28888110
[TBL] [Abstract][Full Text] [Related]
83. Strain-dependent disease and response to favipiravir treatment in mice infected with Chikungunya virus.
Julander JG; Dagley A; Gebre M; Komeno T; Nakajima N; Smee DF; Furuta Y
Antiviral Res; 2020 Oct; 182():104904. PubMed ID: 32791074
[TBL] [Abstract][Full Text] [Related]
84. Cellular and molecular mechanisms of chikungunya pathogenesis.
Lum FM; Ng LF
Antiviral Res; 2015 Aug; 120():165-74. PubMed ID: 26092642
[TBL] [Abstract][Full Text] [Related]
85. Functional processing and secretion of Chikungunya virus E1 and E2 glycoproteins in insect cells.
Metz SW; Geertsema C; Martina BE; Andrade P; Heldens JG; van Oers MM; Goldbach RW; Vlak JM; Pijlman GP
Virol J; 2011 Jul; 8():353. PubMed ID: 21762510
[TBL] [Abstract][Full Text] [Related]
86. The evolution of chikungunya virus circulating in Indonesia: Sequence analysis of the orf2 gene encoding the viral structural proteins.
Hakim MS; Annisa L; Aman AT
Int Microbiol; 2023 Nov; 26(4):781-790. PubMed ID: 36774411
[TBL] [Abstract][Full Text] [Related]
87. Temporal SILAC-based quantitative proteomics identifies host factors involved in chikungunya virus replication.
Treffers EE; Tas A; Scholte FE; Van MN; Heemskerk MT; de Ru AH; Snijder EJ; van Hemert MJ; van Veelen PA
Proteomics; 2015 Jul; 15(13):2267-80. PubMed ID: 25764339
[TBL] [Abstract][Full Text] [Related]
88. HLA class I restriction as a possible driving force for Chikungunya evolution.
Tong JC; Simarmata D; Lin RT; Rénia L; Ng LF
PLoS One; 2010 Feb; 5(2):e9291. PubMed ID: 20195467
[TBL] [Abstract][Full Text] [Related]
89. Effect of Viral Strain and Host Age on Clinical Disease and Viral Replication in Immunocompetent Mouse Models of Chikungunya Encephalomyelitis.
Anderson EJ; Knight AC; Heise MT; Baxter VK
Viruses; 2023 Apr; 15(5):. PubMed ID: 37243143
[TBL] [Abstract][Full Text] [Related]
90. BST-2/tetherin-mediated restriction of chikungunya (CHIKV) VLP budding is counteracted by CHIKV non-structural protein 1 (nsP1).
Jones PH; Maric M; Madison MN; Maury W; Roller RJ; Okeoma CM
Virology; 2013 Mar; 438(1):37-49. PubMed ID: 23411007
[TBL] [Abstract][Full Text] [Related]
91. ISG15 is critical in the control of Chikungunya virus infection independent of UbE1L mediated conjugation.
Werneke SW; Schilte C; Rohatgi A; Monte KJ; Michault A; Arenzana-Seisdedos F; Vanlandingham DL; Higgs S; Fontanet A; Albert ML; Lenschow DJ
PLoS Pathog; 2011 Oct; 7(10):e1002322. PubMed ID: 22028657
[TBL] [Abstract][Full Text] [Related]
92. Chikungunya virus pathogenesis and immunity.
Gasque P; Couderc T; Lecuit M; Roques P; Ng LF
Vector Borne Zoonotic Dis; 2015 Apr; 15(4):241-9. PubMed ID: 25897810
[TBL] [Abstract][Full Text] [Related]
93. Chikungunya virus nsP3 & nsP4 interacts with HSP-90 to promote virus replication: HSP-90 inhibitors reduce CHIKV infection and inflammation in vivo.
Rathore AP; Haystead T; Das PK; Merits A; Ng ML; Vasudevan SG
Antiviral Res; 2014 Mar; 103():7-16. PubMed ID: 24388965
[TBL] [Abstract][Full Text] [Related]
94. Regulation of Viral Replication, Apoptosis and Pro-Inflammatory Responses by 17-AAG during Chikungunya Virus Infection in Macrophages.
Nayak TK; Mamidi P; Kumar A; Singh LP; Sahoo SS; Chattopadhyay S; Chattopadhyay S
Viruses; 2017 Jan; 9(1):. PubMed ID: 28067803
[TBL] [Abstract][Full Text] [Related]
95. Activity of andrographolide against chikungunya virus infection.
Wintachai P; Kaur P; Lee RC; Ramphan S; Kuadkitkan A; Wikan N; Ubol S; Roytrakul S; Chu JJ; Smith DR
Sci Rep; 2015 Sep; 5():14179. PubMed ID: 26384169
[TBL] [Abstract][Full Text] [Related]
96. Interleukin 27 as an inducer of antiviral response against chikungunya virus infection in human macrophages.
Valdés-López JF; Fernandez GJ; Urcuqui-Inchima S
Cell Immunol; 2021 Sep; 367():104411. PubMed ID: 34325085
[TBL] [Abstract][Full Text] [Related]
97. Comparative analysis of the genome sequences and replication profiles of chikungunya virus isolates within the East, Central and South African (ECSA) lineage.
Chen KC; Kam YW; Lin RT; Ng MM; Ng LF; Chu JJ
Virol J; 2013 May; 10():169. PubMed ID: 23721429
[TBL] [Abstract][Full Text] [Related]
98. The acute phase of Chikungunya virus infection in humans is associated with strong innate immunity and T CD8 cell activation.
Wauquier N; Becquart P; Nkoghe D; Padilla C; Ndjoyi-Mbiguino A; Leroy EM
J Infect Dis; 2011 Jul; 204(1):115-23. PubMed ID: 21628665
[TBL] [Abstract][Full Text] [Related]
99. Diagnostic accuracy of a rapid E1-antigen test for chikungunya virus infection in a reference setting.
Huits R; Okabayashi T; Cnops L; Barbé B; Van Den Berg R; Bartholomeeusen K; Ariën KK; Jacobs J; Bottieau E; Nakayama EE; Shioda T; Van Esbroeck M
Clin Microbiol Infect; 2018 Jan; 24(1):78-81. PubMed ID: 28606643
[TBL] [Abstract][Full Text] [Related]
100. Vitamin D modulates the expression of Toll-like receptors and pro-inflammatory cytokines without affecting Chikungunya virus replication, in monocytes and macrophages.
Valdés-López JF; Velilla P; Urcuqui-Inchima S
Acta Trop; 2022 Aug; 232():106497. PubMed ID: 35508271
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
